LONDON, Feb 11 (Reuters) - AstraZeneca expects to produce more than 100 million doses of its COVID-19 vaccine - developed with Oxford University - this month, ramping up to more than 200 million a month by April, Chief Executive Pascal Soriot said on Thursday.
Mene Pangalos, head of BioPharmaceuticals R&D at the British drugmaker earlier said the company expects much-anticipated data for the late-stage U.S. trial of its vaccine before the end of March.
A read-out on data is “only weeks away”, he said on a media call after release of the company’s 2020 results. (Reporting by Pushkala Aripaka and Ludwig Burger Writing by Josephine Mason Editing by David Goodman )
我们的标准: 汤森路透“信任原则”